February 19, 2024 - February 22, 2024

Zenith Drugs IPO Review & Recommendations

Dilip Davda has given "May Apply" recommendation to Zenith Drugs IPO.

Zenith Drugs IPO Review Summary from brokers and analysts

Review By	Apply	May Apply	Neutral	Avoid	Not Rated
Count	0	1	0	0	0
%	0.00	100.00	0.00	0.00	0.00

Zenith Drugs IPO Analysis By Brokers/Analysts

Reviewer	Recommendation	Past Reviews
Dilip Davda	May Apply

Zenith Drugs IPO Review by Dilip Davda (May apply)

[Dilip Davda] The company is in the pharma business with manufacturing and trading activities. It posted growth in its top lines for the reported periods, but sudden boost in its bottom lines from FY23 onwards raise eyebrows and concern over its sustainability. Based on FY24 annualized super earnings, the issue appears fully priced. Well-informed investors may park moderate funds for the medium term rewards. Read detail review...

Zenith Drugs IPO Peer Comparison

Zenith Drugs Limited peer comparison with similar listed entities. (As on March 31, 2023)

Company Name	EPS (Basic)	EPS (Diluted)	NAV (per share) (Rs)	P/E (x)	RoNW (%)	Financial statements
Zenith Drugs Limited	4.29	4.29	14.37	18.40	29.88	Consolidated
Sudarshan Pharma Industries Ltd	5.48	5.48		41.11	13.07	Standalone
Sigachi Industries Limited	13.52	13.52		28.64	18.75	Standalone

Notes:

The figures of Zenith Drugs Limited are based on financial statements as restated as on March 31, 2023.
Considering the nature and size of business of the Company, the peers are not strictly comparable. However same have been included for broad comparison.
Current Market Price (CMP) is the closing price of peer group scrips as on February 06, 2023.
The figures for the peer group are based on the standalone audited financials for the year ended March 31, 2023.

Zenith Drugs IPO Review by Members

Zenith Drugs IPO Reviews, analysis and views by popular members. Read Zenith Drugs Limited IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Zenith Drugs IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	2	1	0	1
%	50.00	25.00	0.00	25.00

Member	Review
Architbhai	Avoid Frothy market February 22, 2024 9:23:16 AM
Keshav Kumar	Apply for Listing Gain at Cut-off Price Good company February 20, 2024 8:41:44 PM
sekar Ramaswami	May Apply for Short Term at Upper Price Band Ok.being a Pharma stock February 18, 2024 4:09:13 PM
Mr G	Apply for Long Term at Upper Price Band Company deals in ORS , in generic medicine as well doing white labelling for some big pharma co. one of the largest ORS manufacturer in their sector, financials is good, valuation is also justified, company is coming up with new facitility of tablets manufacturing from which company will grow with 30 to 35 % every year so one can invest in the company and can mint money, rest all good have a nice time ahead "Jai Baba Ki" February 16, 2024 3:47:51 PM

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.